Collegium Pharmaceutical, Inc. (COLL)
24.69
+0.48
(+1.98%)
USD |
NASDAQ |
Nov 09, 10:23
Collegium Pharmaceutical EPS Diluted (Quarterly) : 0.5956 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.5956 |
| June 30, 2026 | -0.4637 |
| March 31, 2026 | 0.3992 |
| December 31, 2025 | 0.4604 |
| September 30, 2025 | 0.8385 |
| June 30, 2025 | 0.3446 |
| March 31, 2025 | 0.0736 |
| December 31, 2024 | 0.3501 |
| September 30, 2024 | 0.2677 |
| June 30, 2024 | 0.5221 |
| March 31, 2024 | 0.7079 |
| December 31, 2023 | 0.82 |
| September 30, 2023 | 0.5297 |
| June 30, 2023 | 0.3427 |
| March 31, 2023 | -0.5078 |
| December 31, 2022 | -0.2144 |
| September 30, 2022 | 0.0132 |
| June 30, 2022 | -0.1527 |
| March 31, 2022 | -0.3881 |
| December 31, 2021 | -0.7336 |
| September 30, 2021 | 0.2219 |
| June 30, 2021 | 1.764 |
| March 31, 2021 | 0.4088 |
| December 31, 2020 | 0.1965 |
| Date | Value |
|---|---|
| September 30, 2020 | 0.3218 |
| June 30, 2020 | 0.2296 |
| March 31, 2020 | 0.0128 |
| December 31, 2019 | -0.0655 |
| September 30, 2019 | -0.1825 |
| June 30, 2019 | -0.1411 |
| March 31, 2019 | -0.291 |
| December 31, 2018 | 0.2691 |
| September 30, 2018 | -0.4999 |
| June 30, 2018 | -0.40 |
| March 31, 2018 | -0.57 |
| December 31, 2017 | -0.54 |
| September 30, 2017 | -0.45 |
| June 30, 2017 | -0.72 |
| March 31, 2017 | -0.79 |
| December 31, 2016 | -1.017 |
| September 30, 2016 | -1.13 |
| June 30, 2016 | -1.047 |
| March 31, 2016 | -0.6767 |
| December 31, 2015 | -0.4633 |
| September 30, 2015 | -0.46 |
| June 30, 2015 | -0.45 |
| March 31, 2015 | -0.65 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.510 |
| Corcept Therapeutics, Inc. | 1.010 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 0.0858 |
| Eli Lilly & Co. | 7.221 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 21.76M |
| Revenue (Quarterly) | 216.34M |
| Total Expenses (Quarterly) | 194.58M |
| Enterprise Value | 1.795B |
| Gross Profit Margin (Quarterly) | 57.97% |
| Profit Margin (Quarterly) | 10.06% |
| Earnings Yield | 4.02% |
| Operating Earnings Yield | 13.43% |
| Normalized Earnings Yield | 5.299 |